AAAndré Queiroz Andrade

André Queiroz Andrade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


André Queiroz Andrade has a total of 157 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring a Facilitator‐Enabled Flexible iSupport for Dementia Program: An Internal Pilot Mixed‐Methods Study

    by Ying Yu, Lily Xiao, Shahid Ullah, Claudia Meyer, Michael Chapman, Kai Ping Tan, Langduo Chen, Julie Ratcliffe, Alison Kitson, Andre Q. Andrade, et al.

    Aims: To assess the feasibility, fidelity and preliminary impact of a facilitator‐enabled flexible iSupport for dementia program for family carers of people with dementia in a 6‐month intervention period. Design: This study was a multi‐centre, mixed‐methods, parallel‐group, internal, block‐pilot, randomised controlled trial with an embedded qualitative descriptive study. Methods: The study was conducted across two community aged care services and two tertiary hospitals in Australia. Participants were recruited between June 2022 and April 2023. Quantitative data were collected via surveys at baseline and 6 months. Qualitative data were obtained from carer support group meetings and interviews. Results: Eighty‐four carers were enrolled. The recruitment rate was 10% of eligible carers who were approached, and retention in the intervention group at 6 months was 70%. Findings indicate that carers engaged with the program, although engagement varied across components including use of the iSupport manual, participation in online peer support meetings and interaction via WhatsApp. Preliminary analyses suggested a possible trend toward lower behavioural problems among people living with dementia and lower carer distress responses to these behaviours in the intervention group. However, there was no clear evidence of effects on carers' quality of life, perceived social support, self‐efficacy, or the quality of life of people living with dementia. Findings from the pilot informed modifications to enhance the feasibility of the main trial. Conclusion: This internal pilot study demonstrated the feasibility of a facilitator‐enabled iSupport program and provided preliminary estimates suggesting potential benefits for behavioural outcomes. The results informed refinements to the main trial and highlight the importance of flexible, facilitator‐supported interventions for carers of people living with dementia. Further research in a fully powered trial is required to confirm effectiveness. Implications for the Profession and Patient Care: Carers of people living with dementia in the community valued the flexible support provided by iSupport facilitators. This support can be delivered in multiple formats, including online meetings, WhatsApp groups and tailored one‐to‐one facilitator support, allowing flexibility to meet diverse caregiver needs. Such an approach is particularly relevant for nurse‐led multidisciplinary services and settings that provide remote care. In addition, this study offers practical insights into feasibility considerations, such as recruitment, engagement and retention, that may inform the design and implementation of future nursing and community‐based interventions. Impact: This study provides preliminary evidence on how facilitator‐enabled flexible support can be implemented in community settings, informing the design and delivery of future dementia care interventions. Findings suggest that carers can engage with and benefit from structured, facilitator‐supported interventions delivered in flexible formats and may experience potential benefits that warrant further evaluation. Facilitator‐enabled flexible support has the potential to complement existing services for carers of people living with dementia and may help address unmet support needs in community settings. Reporting Method: We adhered to the CONSORT 2010 statement and its extension for randomised pilot and feasibility trials. We also reported in accordance with the Good Reporting of A Mixed Methods Study (GRAMMS). Patient or Public Contribution: Participants in this study included carers of people living with dementia in the community, supported by health and social care professionals from the four participating organisations. Trial Registration: The randomised controlled trial protocol was registered with the Australian and New Zealand Clinical Trials Registry (Registration No. ACTRN12622000199718)

  • Open Access

    Enhancing AI Clinical Decision Support Trust: Design Workshop Insights from General Practitioners

    by R A D L M K Ranwala, Andre Q. Andrade

    Artificial Intelligence (AI) predictive models are increasingly integrated into Clinical Decision Support Systems (CDSS). However, real-world implementation is lagging due to a lack of trust and acceptance by healthcare providers. To investigate factors related to trust and acceptance of AI-based CDSS, we conducted a workshop with General Practitioners to explore user, model, and organizational factors that could affect trust and recommendation acceptance. The workshop discussions revealed that while explainability is crucial for understanding AI decisions, current explainable AI (XAI) visualizations appeared to provide limited value to clinicians without technical backgrounds. Participants suggested that transparency in model training information, including data sources and elements, combined with clear alignment between model decisions and established clinical research findings and guidelines, would enhance their trust and acceptance of AI-based recommendations. These insights provide valuable direction for developing user interfaces that enhance clinician trust and acceptance of AI-based CDSS in clinical practice.


  • Open Access

    Predicting Antidepressant Deprescription with Machine Learning Using Administrative Data

    by R A D L M K Ranwala, A.Q. Andrade

    The high prevalence of failed antidepressant deprescription attempts makes it difficult for clinicians to identify suitable candidates for discontinuation. In this study, we use the Pharmaceutical Benefits Scheme (PBS) dataset, which contains rich longitudinal dispensing data from Australian primary care and developed supervised models to predict successful deprescription. To overcome the challenge of observational administrative data, we developed two distinct annotation pathways (retrospective and prospective) to identify successful and unsuccessful deprescription cases and trained several supervised machine learning models using the labelled data from each pathway. The best accuracy in predicting successful deprescription was reached using XGBoost (0.81) and Random Forest (0.90) for retrospective and prospective annotation, respectively. The study results demonstrate the potential of administrative healthcare data for developing clinical decision support tools, though further validation against clinical outcomes is needed.

  • Open Access

    Tool for longitudinal monitoring of medicine‐related symptoms in older people: a feasibility study

    by Abebe Basazn Mekuria, Renly Lim, Andre Q. Andrade, Debra Rowett, Monique S. Boord, Mariann Hedström, Julian Soriano, Elizabeth E. Roughead

    Background: Older adults are vulnerable to medicine‐related harm due to age‐related changes in pharmacokinetics and pharmacodynamics. Aim: The aim of this study was to adapt and test a tool for longitudinal monitoring of medicine‐related symptoms in older adults. Method: The PHArmacotherapeutical Symptom Evaluation‐20 tool was adapted from a four‐point to an 11‐point scale (PHASE‐20–Australian version) and administered to residents at the initial interview and again at the 4‐week follow up in an aged‐care facility, located in South Australia, Australia. The Edmonton Symptom Assessment Scale (ESAS) tool was used as a comparator to evaluate how the adapted tool tracks symptoms overtime. Symptoms reported using the PHASE‐20–Australian version were compared with adverse effects of medicines in use listed in the Australian product information. The test–retest reliability of the adapted tool was also evaluated. Ethical approval was granted by the University of South Australia Human Research Ethics Committee (Reference no: HREC205098) and the study conforms to the Australian National statement on ethical conduct in human research . Informed consent was obtained from all participants via the distribution of project information sheets and completion of written consent forms. Results: Nineteen residents (mean age ± standard deviation [84.4 ± 8.0 years]) completed the initial assessment and 17 completed the follow up. Seventy‐two percent of the symptoms reported using the PHASE‐20–Australian version matched the common or very common adverse effects listed in the Australian product information for the medicines used by the residents. The PHASE‐20–Australian version showed a strong positive correlation with ESAS scores ( rho = 0.744, p < 0.001). Changes in PHASE‐20–Australian version scores correlated moderately to strongly with changes in ESAS scores ( rho = 0.658, p < 0.004). The adapted tool had acceptable test–retest reliability (intraclass correlation coefficient = 0.738). Conclusion: The score of PHASES‐20–Australian version correlated well with a tool validated for longitudinal monitoring of symptoms and demonstrated acceptable test–retest reliability. Further studies are needed to confirm its validity for longitudinal monitoring of medicine‐related symptoms.


  • Open Access

    Stakeholder’s consensus on activities to be delivered by the facilitators in a planned iSupport program in Australia: A mixed-methods study

    by Ying Yu, Sarah C. Hunter, Alison Kitson, Lily Xiao, Claudia Meyer, Michael Chapman, Kai Ping Tan, Langduo Chen, Sue Mckechnie, Julie Ratcliffe, et al.


  • Open Access

    Co-Designing a Consumer-Focused Digital Reporting Health Platform to Improve Adverse Medicine Event Reporting: Protocol for a Multimethod Research Project (the ReMedi Project)

    by Eyob Alemayehu Gebreyohannes, Christopher Thornton, Myra Thiessen, Sieta T de Vries, Andre Q Andrade, Lisa Kalisch Ellett, Oliver Frank, Phaik Yeong Cheah, Kim-Kwang Raymond Choo, Tracey Lea Laba, et al.

    Background: Adverse medicine events (AMEs) are unintended effects that occur following administration of medicines. Up to 70% of AMEs are not reported to, and hence remain undetected by, health care professionals and only 6% of AMEs are reported to regulators. Increased reporting by consumers, health care professionals, and pharmaceutical companies to medicine regulatory authorities is needed to increase the safety of medicines. Objective: We describe a project that aims to co-design a digital reporting platform to improve detection and management of AMEs by consumers and health care professionals and improve reporting to regulators. Methods: The project will be conducted in 3 phases and uses a co-design methodology that prioritizes equity in designing with stakeholders. Our project is guided by the Consolidated Framework for Implementation Research. In phase 1, we will engage with 3 stakeholder groups—consumers, health care professionals, and regulators—to define digital platform development standards. We will conduct a series of individual interviews, focus group discussions, and co-design workshops with the stakeholder groups. In phase 2, we will work with a software developer and user interaction design experts to prototype, test, and develop the digital reporting platform based on findings from phase 1. In phase 3, we will implement and trial the digital reporting platform in South Australia through general practices and pharmacies. Consumers who have recently started using medicines new to them will be recruited to use the digital reporting platform to report any apparent, suspected, or possible AMEs since starting the new medicine. Process and outcome evaluations will be conducted to assess the implementation process and to determine whether the new platform has increased AME detection and reporting. Results: This project, initiated in 2023, will run until 2026. Phase 1 will result in persona profiles and user journey maps that define the standards for the user-friendly platform and interactive data visualization tool or dashboard that will be developed and further improved in phase 2. Finally, phase 3 will provide insights of the implemented platform regarding its impact on AME detection, management, and reporting. Findings will be published progressively as we complete the different phases of the project. Conclusions: This project adopts a co-design methodology to develop a new digital reporting platform for AME detection and reporting, considering the perspectives and lived experience of stakeholders and addressing their requirements throughout the entire process. The overarching goal of the project is to leverage the potential of both consumers and technology to address the existing challenges of underdetection and underreporting of AMEs to health care professionals and regulators. The project potentially will improve individual patient safety and generate new data for regulatory purposes related to medicine safety and effectiveness. International Registered Report Identifier (IRRID): DERR1-10.2196/60084


  • Open Access

    Co-Designing a Consumer-Focused Digital Reporting Health Platform to Improve Adverse Medicine Event Reporting: Protocol for a Multimethod Research Project (the ReMedi Project) (Preprint)

    by Eyob Alemayehu Gebreyohannes, Christopher Thornton, Myra Thiessen, Sieta T de Vries, Andre Q Andrade, Lisa Kalisch Ellett, Oliver Frank, Phaik Yeong Cheah, Kim-Kwang Raymond Choo, Tracey Lea Laba, et al.

    BACKGROUND Adverse medicine events (AMEs) are unintended effects that occur following administration of medicines. Up to 70% of AMEs are not reported to, and hence remain undetected by, health care professionals and only 6% of AMEs are reported to regulators. Increased reporting by consumers, health care professionals, and pharmaceutical companies to medicine regulatory authorities is needed to increase the safety of medicines. OBJECTIVE We describe a project that aims to co-design a digital reporting platform to improve detection and management of AMEs by consumers and health care professionals and improve reporting to regulators. METHODS The project will be conducted in 3 phases and uses a co-design methodology that prioritizes equity in designing with stakeholders. Our project is guided by the Consolidated Framework for Implementation Research. In phase 1, we will engage with 3 stakeholder groups—consumers, health care professionals, and regulators—to define digital platform development standards. We will conduct a series of individual interviews, focus group discussions, and co-design workshops with the stakeholder groups. In phase 2, we will work with a software developer and user interaction design experts to prototype, test, and develop the digital reporting platform based on findings from phase 1. In phase 3, we will implement and trial the digital reporting platform in South Australia through general practices and pharmacies. Consumers who have recently started using medicines new to them will be recruited to use the digital reporting platform to report any apparent, suspected, or possible AMEs since starting the new medicine. Process and outcome evaluations will be conducted to assess the implementation process and to determine whether the new platform has increased AME detection and reporting. RESULTS This project, initiated in 2023, will run until 2026. Phase 1 will result in persona profiles and user journey maps that define the standards for the user-friendly platform and interactive data visualization tool or dashboard that will be developed and further improved in phase 2. Finally, phase 3 will provide insights of the implemented platform regarding its impact on AME detection, management, and reporting. Findings will be published progressively as we complete the different phases of the project. CONCLUSIONS This project adopts a co-design methodology to develop a new digital reporting platform for AME detection and reporting, considering the perspectives and lived experience of stakeholders and addressing their requirements throughout the entire process. The overarching goal of the project is to leverage the potential of both consumers and technology to address the existing challenges of underdetection and underreporting of AMEs to health care professionals and regulators. The project potentially will improve individual patient safety and generate new data for regulatory purposes related to medicine safety and effectiveness. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/60084


  • Open Access

    Data-Driven Interventions for an Emergency Preparedness System: A National Experience in Australia

    by Andre Q. Andrade, Mhairi Kerr, Elizabeth E. Roughead

    Natural disasters and health emergencies disproportionally affect vulnerable populations causing disruptions to usual care and increasing chronic disease burden. Data and digital technologies are important tools to identify and mitigate indirect effects of emergencies. In this paper, we describe the methods used in the development of a series of digital emergency preparedness interventions to mitigate the direct and indirect consequences of the COVID-19 pandemic in the veteran community in Australia. The case studies demonstrate the use of data for surveillance, patient phenotyping, data-driven decision support and stakeholder communication in primary care. The intervention successfully increased appropriate healthcare use by vulnerable individuals and could be expanded to other populations.


  • Open Access

    Correlation of frailty assessment metrics in one-year follow-up of aged care residents: a sub-study of a randomised controlled trial

    by A. Q. Andrade, I. Widagdo, R. Lim, T.-L. Kelly, G. Parfitt, N. Pratt, R. L. Bilton, E. E. Roughead

    Introduction: Frailty is increasingly recognised as a dynamic syndrome, with multiple causes, dimensions and consequences. There is little understanding of how those frailty assessment metrics interact over time. The aim of this study was to describe the longitudinal correlation between five frailty metrics, namely multimorbidity, muscular strength, mood alterations, cognitive capacity, and functional capacity in a cohort study of aged care (nursing home) residents. Methods: 248 aged care residents with Frailty Index at baseline of < 0.4 and no dementia were followed for 12 months. A multimorbidity score and an activity of daily living limitation score were created using individual items of the Frailty Index. Muscular strength was measured by grip strength. Cognitive capacity was measured using the Montreal Cognitive Assessment (MoCA) test. Mood alterations were measured using the anxiety/depression screening question from EQ-5D. We analysed the inter-individual correlation at baseline, association between baseline and future change, and within-individual correlation at baseline, 6 and 12 months. Results: Population analysis shows that metrics were not associated at baseline. All of the studied metrics at baseline were associated with change in 12 months, with the exception of anxiety/depression scores. Pairwise within-individual correlation was strong between MoCA and grip strength (0.13, p = 0.02) and activity of daily living (− 0.48, p < 0.001), and between activities of daily living and multimorbidity index (0.28, p < 0.001). No within-individual correlation was found between anxiety depression score and other metrics. Conclusion: The results suggest an interdependence between comorbidities, physical capacity, cognition and activities of daily living in aged care residents. Comprehensive measurement of frailty-related metrics may provide improved understanding of frailty progression at later life stages.


  • Open Access

    Reducing opioid use for chronic non-cancer pain in primary care using an evidence-based, theory-informed, multistrategic, multistakeholder approach: a single-arm time series with segmented regression

    by Anna K Moffat, Jemisha Apajee, Vanessa T Le Blanc, Kerrie Westaway, Andre Q Andrade, Emmae N Ramsay, Natalie Blacker, Nicole L Pratt, Elizabeth Ellen Roughead

    Background Many countries have high opioid use among people with chronic non-cancer pain. Knowledge about effective interventions that could be implemented at scale is limited. We designed a national intervention that included audit and feedback, deprescribing guidance, information on catastrophising assessment, pain neuroscience education and a cognitive tool for use by patients with their healthcare providers. Method We used a single-arm time series with segmented regression to assess rates of people using opioids before (January 2015 to September 2017), at the time of (October 2017) and after the intervention (November 2017 to August 2019). We used a cohort with historical comparison group and log binomial regression to examine the rate of psychologist claims in opioid users not using psychologist services prior to the intervention. Results 13 968 patients using opioids, 8568 general practitioners, 8370 pharmacies and accredited pharmacists and 689 psychologists were targeted. The estimated difference in opioid use was −0.51 persons per 1000 persons per month (95% CI −0.69, –0.34; pConclusions Our intervention addressed the cognitive, affective and sensory factors that contribute to pain and consequent opioid use, demonstrating it could be implemented at scale and was associated with a reduction in opioid use and increasing utilisation of psychologist services.